Robert Taylor - Enfusion Head Support
| ENFNDelisted Stock | USD 10.76 0.00 0.00% |
Executive
Robert Taylor is Head Support of Enfusion
| Phone | 312 253 9800 |
| Web | https://www.enfusion.com |
Enfusion Management Efficiency
The company has return on total asset (ROA) of 0.0305 % which means that it generated a profit of $0.0305 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0442 %, meaning that it created $0.0442 on every $100 dollars invested by stockholders. Enfusion's management efficiency ratios could be used to measure how well Enfusion manages its routine affairs as well as how well it operates its assets and liabilities.Enfusion currently holds 20.31 M in liabilities. Enfusion has a current ratio of 8.99, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Enfusion's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Joon Huh | Freshworks | N/A | |
| Aleksey Lakchakov | CS Disco LLC | N/A | |
| Denise Cox | Meridianlink | N/A | |
| Jeffrey Robinson | PROS Holdings | 58 | |
| Eric Sanders | Braze Inc | N/A | |
| Colleen Langevin | PROS Holdings | N/A | |
| Mike Chen | Clearwater Analytics Holdings | N/A | |
| Margaret Driscoll | Blackbaud | N/A | |
| Susan Garcia | CS Disco LLC | 53 | |
| Alphonse JD | Clearwater Analytics Holdings | 54 | |
| Nandan Amladi | Meridianlink | N/A | |
| Doug Piper | Meridianlink | N/A | |
| Mike Badgis | ON24 Inc | N/A | |
| May ONeal | ON24 Inc | N/A | |
| Dan Mickwee | ON24 Inc | N/A | |
| David Benjamin | Blackbaud | 53 | |
| Philippa Lawrence | Freshworks | 57 | |
| Karen Herckis | CS Disco LLC | 53 | |
| Priyanka Singh | Braze Inc | 56 | |
| Susan JD | Braze Inc | 65 | |
| Kristin Seigworth | E2open Parent Holdings | N/A | |
Management Performance
| Return On Equity | 0.0442 | |||
| Return On Asset | 0.0305 |
Enfusion Leadership Team
Elected by the shareholders, the Enfusion's board of directors comprises two types of representatives: Enfusion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enfusion. The board's role is to monitor Enfusion's management team and ensure that shareholders' interests are well served. Enfusion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enfusion's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stephen Dorton, Chief Officer | ||
| Michael Berry, Chief Officer | ||
| Lorelei Skillman, Chief Officer | ||
| Vivek Ranka, Head Technology | ||
| Stephen Malherbe, Managing Partner | ||
| Oleg Movchan, Interim Director | ||
| Matthew Campobasso, General Secretary | ||
| Bronwen Bastone, Chief Officer | ||
| Joseph Defeo, Global Production | ||
| Lotte Tonsberg, Head EMEA | ||
| Kabir Kohli, MD Services | ||
| Jeff Young, Head Implementation | ||
| Iris Wang, Chief Officer | ||
| Brian Murphy, Investor | ||
| Matt Campobasso, General Counsel | ||
| Robert Taylor, Head Support | ||
| Ignatius Njoku, Head Relations | ||
| Bradley Herring, Chief Officer | ||
| Neal Pawar, Chief Officer | ||
| Daniel Groman, Chief Officer | ||
| Valeria Gutowski, Chief Officer |
Enfusion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enfusion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0442 | |||
| Return On Asset | 0.0305 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.03 % | |||
| Current Valuation | 1.01 B | |||
| Shares Outstanding | 94.8 M | |||
| Shares Owned By Insiders | 4.73 % | |||
| Shares Owned By Institutions | 96.25 % | |||
| Number Of Shares Shorted | 1.3 M | |||
| Price To Earning | 0.11 X |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Enfusion Stock
If you are still planning to invest in Enfusion check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Enfusion's history and understand the potential risks before investing.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |